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CASE REPORT
Abstract：
　Excess secretion of growth hormone （GH） causes acromegaly, which is associated with increased morbidity 
and mortality. Primary GH hypersecretion from pituitary adenomas （PAs） is the most common cause of 
acromegaly, but sometimes microadenomas （<₁₀ mm） cannot be detected by magnetic resonance imaging 
（MRI） of the head, resulting in delayed treatment by surgical resection. In this study, selective catheter hormone 
sampling of the venous sinus provided evidence of the localization of GH-secreting PAs.
　A ₄₇-year-old male, admitted to a previous hospital due to a hypertensive right thalamic hemorrhage, was 
incidentally suspected of acromegaly due to his physiological findings. Acromegaly is diagnosed by a 
combination of enlarged extremities and extremely high serum levels of GH and insulin-like growth factor-₁ 
（IGF-₁）. A GH-secreting microadenoma was suspected by repetitive MRIs and selective intravenous hormone 
sampling in the head, resulting in left-side dominant high serum levels of GH. In an endoscopic trans-sphenoidal 
surgery （TSS）, the tumor was first apparent on the right side inside the normal pituitary gland, but we followed 
the lesion based on the results of the catheter examination. The tumor stretched to the left side and attached to 
the medial wall of the left cavernous sinus. The tumorous lesion was resected, and this was confirmed by a post-
operative MRI and peripheral serum GH/IGF-₁ level measurement. Serum GH and IGF-₁ levels decreased at 
₁₀₈ days after surgical resection. Pathological diagnosis resulted in the observation of a sparsely granulated GH-
secreting PA.
　There are often cases where it is difficult to diagnose acromegaly with localization of the pathological lesion. 
The reason is that more than ₅₀% of GH-secreting PAs are <₁₀ mm, making it difficult to visualize the tumor in 
imaging examinations.
　Here, we diagnosed a GH-secreting PA in a patient who received TSS and subsequently regained normal 
serum GH/IGF-₁ levels.
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Introduction
　Excess secretion of growth hormone （GH） causes 
acromegaly, which is associated with increased morbidity and 
mor t a l i t y  r e l a t ed  t o  ca rd iovascu l a r,  r e sp i r a to ry, 
cerebrovascular, and colonic cancer ₁ ）. Acromegaly can be 
caused by different types of adenomas, including pure GH-cell 
adenomas or tumors with both GH and prolactin （PRL） 
secretion ₁ ）. GH-secreting pituitary adenomas （PAs） constitute 
₈-₁₆% of all PAs. While primary GH hypersecretion from PAs 
is  the most  common cause of  acromegaly,  several 
heterogeneous disorders—such as pituitary hyperplasia, 
excess ectopic GH release from the bronchial carcinoid, and 
ectopic GH secretion by malignant tumors—have been 
reported to cause excessive GH secretion ₂ ）. It is therefore 
essential to diagnose acromegaly with the location of the 
pathology for proper treatment. Acromegaly caused by GH-
secreting PAs is diagnosed by an enlargement of the hands, 
feet, and tongue, accompanied by high serum levels of GH and 
insulin-like growth factor （IGF-₁） and the detection of PAs in 
neuroimaging examinations of the head, according to the 
guide l ines  publ i shed  by  the  Japanese  Socie ty  for 
Hypothalamic and Pituitary Tumors （JSHPT）. However, 
microadenomas （<₁₀ mm） can sometimes remain undetected 
by magnetic resonance imaging （MRI） of the head and cause 
a delay in treatment by surgical resection. Although selective 
intravenous hormone sampling by catheter intervention is a 
useful and required procedure for diagnosing hypersecretion 
of adrenocorticotropic hormone （ACTH） from PAs 
（Cushing＇s disease）, hormone sampling of GH and IGF-₁ is 
still not recommended for the diagnosis of GH-secreting PAs 
according to the official guidelines. 
　Here we present a case study of a patient with GH-secreting 
microadenoma as suspected by repetitive MRIs and selective 
intravenous hormone sampling, who received surgical 
resection and showed the decrease of hormone levels.
Case presentation
　A ₄₇-year-old male admitted to a previous hospital due to a 
hypertensive right thalamic hemorrhage was kept under 
observation with blood pressure management according to the 
patient ＇s stable condition and the localization of the 
hemorrhage. He was incidentally suspected of acromegaly due 
to his physiological findings （Fig. ₁A） and transferred to 
Yokohama City University Hospital. We took X-rays of foot, 
hand and head which showed characteristic findings of 
acromegaly （Fig. ₁B-D）. According to the guidelines for the 
Fig. ₁ : Pre-therapeutic images
A: Photo shows physiological findings of enlarged lip, nose, tongue, forehead, and lower jaw in the face.  B: Right foot X-ray shows heel pad 
thickness （₂₂ mm）.  C: Right hand X-ray shows cauliflower-like tufting.  D: Head X-ray shows frontal sinus protrusion （arrow head） and outer 
occipital uplift （arrow）.  E: Head MRI T ₁ -weighted contrast enhancement image shows a tumor in the pituitary gland.
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diagnosis and treatment of acromegaly from JSHPT, a set of 
measurements was taken, including serum GH/IGF-₁ levels, 
nadir serum GH level during ₇₅ g oral glucose tolerance test 
（OGTT）, and an MRI. Peripheral serum GH and IGF-₁ levels 
at rest were ₃.₃₁ ng/mL （Normal range: ＜₂.₄₇ng/mL） and 
₃₅₇ ng/mL （Normal range: ₉₀-₂₅₀ng/mL）, respectively, while 
the blood sugar level and serum GH level after two hours on 
₇₅ g OGTT were ₁₅₂ mg/dL and ₅.₅₁ ng/mL （Normal range: 
＜ ₁ng/mL）, respectively. Increase of nadir serum GH level 
after two hours on ₇₅ g OGTT is one of the diagnostic criteria 
of acromegaly. While the patient was diagnosed with 
acromegaly, MRI of the head for the detection of GH-
secret ing PAs did  not  show any s igns  of  a  tumor. 
Subsequently, the patient received bi-weekly subcutaneous 
injections of ₉₀ mg lanreotide, and his serum GH level at rest 
decreased to ₂.₀₄ ng/mL for twelve months. However, serum 
GH levels increased again to ₇.₁₀ ng/mL in the fourteen 
months following initiation of the lanreotide treatment. 
Repetitive MRIs revealed a tiny lesion in the right side of the 
pituitary gland （Fig. ₁E）. Therefore, we conducted selective 
catheter intravenous sampling and found that serum GH and 
IGF-₁ levels were much higher than the normal range with a 
left-side dominance as shown in Table ₁. We conducted an 
endoscopic trans-sphenoidal surgery （TSS） for GH-secreting 
PAs. During the surgery, the tumor was first apparent on the 
right side inside the normal pituitary gland, but we followed 
the lesion according to the results of the catheter examination. 
The tumor stretched to the left side and attached to the medial 
wall of the left cavernous sinus. The tumorous lesion was 
resected, which was confirmed by a postoperative MRI and 
peripheral serum GH/IGF-₁ measurements. Serum GH/IGF-₁ 
levels decreased to ₁.₂₆ ng/mL and ₁₃₄ ng/mL at ₁₀₈ days 
after surgical resection, respectively.
Pathological Findings
　We performed pathological diagnosis from the tumor 
sample. Under microscopic examination after hematoxylin-
eosin staining, we observed a sparsely granulated adenoma 
with chromophobic features and nuclear pleomorphism （Fig. 
₂A）. Low molecular weight keratins, displayed a cytoplasmic, 
perinuclear pattern after Cam ₅.₂ staining （Fig. ₂B）. GH was 
expressed focally （Fig. ₂C）, and PRL was not expressed in the 
tumor tissue （Fig. ₂D）. Taken together, we used these findings 
to diagnose the tumor as a sparsely granulated GH-secreting 
PA.
Discussion
　There are often cases where it is difficult to diagnose 
acromegaly with localization of the pathological lesion. The 
first reason for this is that about ₅₀% of PAs are <₁₀ mm ₂ ）. Of 
Fig. ₂ : Histopathological analysis
A: Sparsely granulated somatotroph adenoma with nuclear pleomorphism 
in hematoxylin-eosin stain  B: Low molecular weight keratin displays a 
cytoplasmic, perinuclear pattern in Cam ₅.₂ stain.  C: GH is expressed focally.  D: 
PRL is not expressed in the tumor tissue.
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Fig. ₃ : Catheter intervention images
A: Arrow head shows the leading edge of a micro-catheter for bilateral 
cavernous sinus sampling.
B: Arrow head shows the leading edge of a micro-catheter for bilateral inferior 
petrosal sinus sampling.
C: In the schema, arrow head shows cavernous sinus sampling and arrow shows 
inferior petrosal sinus sampling.
C
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GH-secreting PAs （comprising ₈-₁₆% of all PAs）, more than 
half are expected to be <₁₀ mm at the time of diagnosis. 
Although computer tomography （CT） scanning of the head 
may show moderate contrast-enhancement, or positron 
emission tomography （PET） may show high uptake of 
fluorodeoxyglucose, microadenomas （<₁₀ mm） may not be 
detected because of the low resolution of the images₃, ₄ ）. The 
second difficulty in diagnosing acromegaly with localization 
of the pathological lesion is that GH hypersecretion can also 
be a product of systemic diseases such as bronchial carcinoids 
or ectopic GH-secreting malignant tumors.
　Selective intravenous sampling enables us to measure the 
values of GH and IGF-₁ levels. Though selective intravenous 
sampling is recommended for only ACTH-secreting PAs in the 
guideline, still now, the technique is not recommended for the 
diagnosis of GH-secreting PA. In the diagnosis process of 
ACTH-secreting PAs, the selective intravenous sampling is 
most reliable examination with high sensitivity and 
specificity ₂ ）. While GH-secreting PAs is relatively larger 
microadenomas comparing to ACTH-secreting PAs. And 
la rger  microadenomas  can  be  found in  images  or 
intraoperative situation, so lateralization by selective 
intravenous sampling is usually not so critical ₅ ）.
　In the case of microadenomas, selective intravenous 
sampling is useful for localization of the tumor. There are 
supposed to be a reason in the discrepancy between the 
hormone sampling values in cavernous sinus and inferior 
petrosal sinus.
　Cavernous sinus and inter cavernous sinus makes 
complicated network structure like a net and trivial positioning 
difference of micro-cathertel causes data-variabilities. While 
inferior petrosal sinus is a outlet, so it is more reliable as othe 
reports noted before.
　The possible complications of this test include thrombosis 
leading to arterial and venous cerebral infarction, and cerebral 
hemorrhage caused by damaged cerebral vessels ₆ ）. Moreover, 
there are a lot of variations in the intracranial venous drainage 
system which makes it difficult to interpret the results of the 
catheter sampling. Therefore, every catheter result should be 
discussed in consultation with experts. While GH level on left 
side is higher than that of right side, the values of IGF-₁, a 
liver mainly producing factor, are mostly equal in both sides.
　Trans-sphenoidal surgery （TSS） is the first-line treatment 
for GH-secreting PAs in patients with acromegaly. With recent 
refinements in surgical instruments and techniques, surgical 
results are improving, and in approximately ₇₀% of patients 
there is a chance of achieving biochemical remission after a 
single TSS performed by an experienced surgeon. Therefore, 
evidence of the localization of GH-secreting PAs using 
selective intravenous sampling may help the treatment 
strategy.
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Target cathertel position serum GH（ng/mL） IGF-₁（ng/mL）
right cavernous sinus ₀.₈₆ ₃₄₉
right inferior petrosal sinus ₂.₇₆ ₃₃₉
left cavernous sinus ₀.₈₅ ₃₃₇
left inferior petrosal sinus ₁₀₈ ₃₄₅
peripheral blood ₁.₂ ₃₃₁
Table ₁: Cathertel venous sampling of serum GH and IGF-I
